Prime Radiant Invests $50M in Cellares Series D

Prime Radiant Partners, a newly established private equity advisory firm, has officially entered the investment arena with its inaugural transaction. The firm has committed a substantial $50 million in growth capital to Cellares, a company operating at the forefront of advanced manufacturing solutions for the biopharmaceutical sector. This significant investment underscores Prime Radiant's strategic focus on the dynamic healthcare and life sciences industries.

The capital infusion into Cellares, a key player in enabling cell and gene therapy production, forms a crucial part of the company's broader $327 million Series D financing round. This funding initiative is designed to accelerate Cellares' expansion and solidify its position in a market experiencing rapid technological advancement and increasing demand for specialized manufacturing capabilities. The biopharmaceutical manufacturing sector, particularly for complex modalities like cell and gene therapies, is projected to grow significantly, driven by breakthroughs in personalized medicine and a robust drug development pipeline.

Founded in 2025 by seasoned healthcare investment and operating professionals Giovanni Fazio, Walid Gardezi, and Peter Soelkner, Prime Radiant Partners brings a wealth of experience, exceeding 70 years collectively, across private equity, pharmaceutical services, and life sciences. Their debut deal with Cellares signals a clear strategy to back innovative companies poised to disrupt established markets within their specialized sectors.

Cellares' Series D round attracted a distinguished group of investors, demonstrating strong market confidence in its technology and vision. Alongside Prime Radiant Partners, the funding includes participation from prominent institutional investors such as BlackRock, T. Rowe Price, Baillie Gifford, DFJ Growth, and ARK Invest. This broad base of support from leading financial institutions highlights the perceived value and future potential of Cellares' manufacturing platform, which aims to streamline and scale the production of life-saving therapies.

The investment in Cellares is particularly noteworthy given the increasing challenges in scaling cell and gene therapy manufacturing. These advanced therapies, while offering unprecedented treatment possibilities, often face bottlenecks in production due to complexity and cost. Cellares' innovative approach seeks to address these critical issues, potentially unlocking wider patient access to these transformative treatments. The global cell and gene therapy market is expected to reach tens of billions of dollars in the coming years, making efficient and scalable manufacturing a paramount concern for the industry.

This strategic partnership between Prime Radiant Partners and Cellares is expected to catalyze further innovation and operational enhancements within the company. The influx of capital will likely fuel research and development, expand manufacturing capacity, and support global commercialization efforts. For Prime Radiant, this initial investment sets a precedent for its future deal-making, signaling an intent to be a significant capital provider in high-growth life science ventures.